In cancer, point mutations in the KRAS gene disrupt this cycle, keeping the KRAS protein in a constitutively activated GTP-bound state that drives tumorigenesis, while in normal cells, KRAS protein is predominantly in the GDP-bound state 3. This evidence concerns the gene KRAS and cancer.